Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Bladder Cancer

  Free Subscription


15.12.2025

1 ACS Nano
1 Adv Radiat Oncol
1 Adv Sci (Weinh)
1 Ann Med Surg (Lond)
1 Arch Toxicol
1 Autophagy
1 Biochem Pharmacol
1 Biofactors
1 Biomater Res
2 BJU Int
1 BJUI Compass
1 Bladder Cancer
1 BMC Cancer
1 BMJ Case Rep
1 Cancer
1 Cancer Cell Int
1 Cancer Lett
1 Cancer Med
1 Cancers (Basel)
1 Cell Biochem Biophys
2 Cell Death Dis
1 Chem Commun (Camb)
1 Clin Genitourin Cancer
1 Clin Nucl Med
1 Clin Transl Med
1 Cureus
2 Diagnostics (Basel)
2 Discov Oncol
1 Dose Response
1 Ecotoxicol Environ Saf
1 Eur J Med Res
1 Eur Urol
2 Eur Urol Focus
1 Eur Urol Oncol
1 Eur Urol Open Sci
1 Expert Rev Mol Diagn
1 FEBS Open Bio
3 Fr J Urol
1 Front Genet
3 Front Immunol
2 Front Oncol
1 Healthcare (Basel)
4 Histopathology
1 Indian J Pathol Microbiol
1 Int J Mol Sci
1 Int J Nanomedicine
1 Int J Surg
5 Int J Urol
2 Int Urol Nephrol
1 J Cachexia Sarcopenia Muscle
1 J Ethnopharmacol
1 J Exp Clin Cancer Res
1 J Natl Cancer Inst
1 J Transl Med
1 J Urol
1 JAMA Ophthalmol
1 JCO Oncol Pract
2 Medicine (Baltimore)
1 Mol Oncol
1 Molecules
1 NPJ Digit Med
1 Oncoimmunology
1 Oncol Rev
1 Oncologist
1 Phys Med
1 Planta Med
2 PLoS One
1 Radiother Oncol
1 Res Rep Urol
1 Res Vet Sci
2 Sci Rep
1 Semin Nucl Med
1 Theranostics
2 Transl Androl Urol
1 Transl Oncol
10 Urol Oncol
1 Urology
1 Value Health
1 Vet Immunol Immunopathol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    ACS Nano

  1. ZHENG R, Xiao Y, Yang J, Mao Z, et al
    Extracellular Vesicle-Packaged MIR4435-2HG Facilitates Cigarette Smoke-Induced Bladder Cancer Progression through Enolase 1-Dependent Glycolytic Reprogramming.
    ACS Nano. 2025 Dec 5. doi: 10.1021/acsnano.4c15108.
    PubMed         Abstract available


    Adv Radiat Oncol

  2. HAYWORTH SB, Hotsinpiller WS, Pogue J, Tyler M, et al
    Early Experience Comparing Reduced Planning Target Volume Margins Using Cone Beam Computed Tomography Scan Guided Online Adaptive Radiation Therapy to Nonadaptive, Traditional Margin Plans for Muscle-Invasive Bladder Cancer.
    Adv Radiat Oncol. 2025;11:101934.
    PubMed         Abstract available


    Adv Sci (Weinh)

  3. JIANG Y, Zhang Q, Zhang Y, Yu X, et al
    NIR-Activatable Domino Cascade Catalysis Nanozyme Reactor for Multi-Mechanism Synergistic Immunotherapy in Bladder Cancer.
    Adv Sci (Weinh). 2025 Dec 12:e13913. doi: 10.1002/advs.202513913.
    PubMed         Abstract available


    Ann Med Surg (Lond)

  4. TAJ J, Ikkurthy N, Ekouo J
    Reappraising intravesical gemcitabine in BCG-unresponsive nonmuscle-invasive bladder cancer: lessons from contemporary re-analysis.
    Ann Med Surg (Lond). 2025;87:9189-9190.
    PubMed        


    Arch Toxicol

  5. ZHENG Y, Wu Y, Zhang J, Zhao C, et al
    Cigarette smoking combines with genetic variants to regulate FOXN3 and associate with bladder cancer risk.
    Arch Toxicol. 2025 Dec 8. doi: 10.1007/s00204-025-04244.
    PubMed         Abstract available


    Autophagy

  6. DONG Y, Tian S, Peng X, Wang P, et al
    CCPG1-mediated reticulophagy promotes tumorigenesis and cisplatin resistance in bladder cancer.
    Autophagy. 2025 Dec 8. doi: 10.1080/15548627.2025.2601865.
    PubMed         Abstract available


    Biochem Pharmacol

  7. JIANG WS, Yu FX, Liu YX, Song YS, et al
    Celastrol synergizes with MEK1 inhibitor nedometinib to overcome resistance in bladder cancer via dual suppression of CDK1/CDC5L and feedback-activated Akt/STAT3.
    Biochem Pharmacol. 2025 Dec 10:117629. doi: 10.1016/j.bcp.2025.117629.
    PubMed         Abstract available


    Biofactors


  8. Correction to "Knockdown of Integrin beta1 Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer Cells".
    Biofactors. 2025;51:e70068.
    PubMed        


    Biomater Res

  9. DENG H, Huang J, Gao N, Liu Z, et al
    Erratum to "Nanotherapeutic System with Effective Microwave Sensitization and Pyroptosis Programming Enable Synergistic Microwave-Immunotherapy in Bladder Cancer".
    Biomater Res. 2025;29:0296.
    PubMed         Abstract available


    BJU Int

  10. DI BELLO F, Gallioli A, Cannoletta D, Mancon S, et al
    Intravesical recurrence after therapeutic ureteroscopy for upper tract urothelial carcinoma: a meta-analysis.
    BJU Int. 2026;137:26-35.
    PubMed         Abstract available

  11. MIEDERER M, Pretze M, Abbate E, Hartig A, et al
    Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CT.
    BJU Int. 2026;137:166-172.
    PubMed         Abstract available


    BJUI Compass

  12. TURAN S, Gezmis CT, Cilesiz NC, Uzut M, et al
    Haematuria cancer risk score as a predictor of muscle-invasive bladder cancer.
    BJUI Compass. 2025;6:e70125.
    PubMed         Abstract available


    Bladder Cancer

  13. DADABHOY A, Doshi C, Zahir M, Sheybaee Moghaddam F, et al
    Impact of neighborhood deprivation on bladder cancer outcomes: A regional analysis.
    Bladder Cancer. 2025;11:23523735251406621.
    PubMed         Abstract available


    BMC Cancer

  14. BLONDEAU A, Pitout A, Manuguerra A, Eschwege P, et al
    Sarcopenia measured by artificial intelligence as a predictor of overall survival in localized bladder cancer, a multicenter study.
    BMC Cancer. 2025 Dec 11. doi: 10.1186/s12885-025-15363.
    PubMed         Abstract available


    BMJ Case Rep

  15. GIGOLA F, Mussini C, Hery G, Rigaud C, et al
    Primary bladder perivascular epithelioid cell tumour in an early adolescent.
    BMJ Case Rep. 2025;18:e262972.
    PubMed         Abstract available


    Cancer

  16. ZHANG L, Liu Z, Ding Y, Sun J, et al
    Natural killer cell infiltration elicits gender-dependent dichotomous clinical outcomes in urothelial carcinoma.
    Cancer. 2025;131:e70196.
    PubMed         Abstract available


    Cancer Cell Int

  17. JAZI NN, Alavimanesh S, Vafadar A, Choubani M, et al
    Theranostic potential of MXene-based platforms for dual MiRNA targeting in metastatic bladder cancer.
    Cancer Cell Int. 2025 Dec 11. doi: 10.1186/s12935-025-04084.
    PubMed         Abstract available


    Cancer Lett

  18. ZHOU ZH, Wen JH, Zhang YZ, Yao K, et al
    Mitochondria-located circRCP regulates redox homeostasis via stabilizing LRPPRC/SLIRP complex to promote bladder urothelial carcinoma tumorigenesis.
    Cancer Lett. 2026;638:218157.
    PubMed         Abstract available


    Cancer Med

  19. TAIHAO W, Chunkai D, Jingcheng L, Yichen Z, et al
    The Prognosis of Urothelial Carcinoma Between Kidney Transplantation Recipients and Normal Patients: A Propensity Score-Matched Study.
    Cancer Med. 2025;14:e71414.
    PubMed         Abstract available


    Cancers (Basel)

  20. REGAZZO R, Ciccarese F, Paglialonga S, Reno E, et al
    High Prevalence of Smoking-Related Diseases in High-Grade and Muscle-Invasive Bladder Cancer: Opportunities for Lung Cancer Screening.
    Cancers (Basel). 2025;17:3741.
    PubMed         Abstract available


    Cell Biochem Biophys

  21. YAN Y, Zhang H, Jia C, Xu H, et al
    Elevated NDRG1 Expression Drives Oxaliplatin Chemoresistance in Bladder Cancer Cells by Promoting Homologous Recombination Repair and Inhibiting G(2)/M Arrest.
    Cell Biochem Biophys. 2025 Dec 10. doi: 10.1007/s12013-025-01961.
    PubMed        


    Cell Death Dis

  22. TAO Y, Huang J, Hou J, Hu Z, et al
    Matrix stiffness maintains bladder cancer stemness via integrin-nuclear skeleton axis.
    Cell Death Dis. 2025;16:887.
    PubMed         Abstract available

  23. TANG Y, Deng X, Wang Y, Zhou Q, et al
    NSUN2-mediated m5C modification of SOCS3 mRNA modulates macrophage polarization in bladder cancer.
    Cell Death Dis. 2025 Dec 7. doi: 10.1038/s41419-025-08306.
    PubMed         Abstract available


    Chem Commun (Camb)

  24. ZHANG J, Ju X, Wang Z, Hao L, et al
    A multiple signal-amplified electrochemiluminescence biosensor for ultrasensitive detection of bladder cancer-associated circRNA in urine.
    Chem Commun (Camb). 2025 Dec 9. doi: 10.1039/d5cc05842.
    PubMed         Abstract available


    Clin Genitourin Cancer

  25. SQUIRES P, Cook EE, Song Y, Wang CY, et al
    Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis.
    Clin Genitourin Cancer. 2025;24:102466.
    PubMed         Abstract available


    Clin Nucl Med

  26. RAEISI N, Saber Tanha A, Khooei A, Ataei N, et al
    Favorable 99m Tc-FAPI-46 Uptake in Primary Mucinous Adenocarcinoma of the Bladder.
    Clin Nucl Med. 2026;51:e55-e56.
    PubMed         Abstract available


    Clin Transl Med

  27. JEONG MS, Mun JY, Yang GE, Baek SW, et al
    Lipocalin 2 as a potential liquid biopsy marker for early detection of bladder cancer.
    Clin Transl Med. 2025;15:e70540.
    PubMed        


    Cureus

  28. MOHAMMED S, Aniah M, Saougki C, Ibrahim AE, et al
    Understanding Treatment Completion and Tolerability of Intravesical Bacillus Calmette-Guerin (BCG) for Non-muscle Invasive Bladder Cancer in a Single UK Health Board.
    Cureus. 2025;17:e98655.
    PubMed         Abstract available


    Diagnostics (Basel)

  29. YANG X, Guo Y, Wang L, Miao Z, et al
    Overexpression of CDC20 Confer a Poorer Prognosis in Bladder Cancer Identified by Gene Co-Expression Network Analysis.
    Diagnostics (Basel). 2025;15:3016.
    PubMed         Abstract available

  30. IKUMA S, Akatsuka J, Kaneko G, Takeda H, et al
    A Composite Risk Score Based on VI-RADS, Tumor Contact Length, and CYFRA 21-1 for Prognostic Stratification in Bladder Cancer.
    Diagnostics (Basel). 2025;15:2968.
    PubMed         Abstract available


    Discov Oncol

  31. QIN R, Li C, Liu C, Shen C, et al
    Combining machine learning and molecular docking to unravel the molecular network of bladder cancer induced by 2-naphthylamine.
    Discov Oncol. 2025 Dec 10. doi: 10.1007/s12672-025-04260.
    PubMed        

  32. XIAO L, Wang Y, Xiong Y, Zhuang Z, et al
    Integrated multi-omics analysis identifies DARS2, MRTO4, and MRPL37 as novel biomarkers and potential therapeutic targets for bladder cancer.
    Discov Oncol. 2025 Dec 9. doi: 10.1007/s12672-025-04246.
    PubMed         Abstract available


    Dose Response

  33. ZHAO W, Xie Z, Zhu L, Li W, et al
    TSN Disrupts Fanconi Anemia Pathway Activation Through JAK/STAT1-Mediated Transcriptional Repression of FA Core Subunits in Bladder Cancer.
    Dose Response. 2025;23:15593258251406039.
    PubMed         Abstract available


    Ecotoxicol Environ Saf

  34. ZHU J, Yi B, Ma J, Zhang S, et al
    Ozone aging amplifies the tumor-promoting effects associated with low-dose graphene oxide exposure in bladder tumors via the integrin alphaV signaling pathway.
    Ecotoxicol Environ Saf. 2025;307:119458.
    PubMed         Abstract available


    Eur J Med Res

  35. WANG P, Li C, Xu Y, Altuwaijri S, et al
    CEACAM6 regulates glycolytic metabolism in bladder cancer cell by controlling ENO1 stability.
    Eur J Med Res. 2025;30:1233.
    PubMed         Abstract available


    Eur Urol

  36. KHENE ZE, Bensalah K, Roupret M
    Artificial Intelligence for Risk Prediction in Non-muscle-invasive Bladder Cancer: From Complexity to Clinical Clarity.
    Eur Urol. 2025 Dec 3:S0302-2838(25)04831-6. doi: 10.1016/j.eururo.2025.
    PubMed        


    Eur Urol Focus

  37. MEEKS JJ
    Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer?
    Eur Urol Focus. 2025 Dec 4:S2405-4569(25)00346-3. doi: 10.1016/j.euf.2025.
    PubMed         Abstract available

  38. LAURIDSEN SV, Tonnesen H, Thind P, Rasmussen M, et al
    Impact of a Perioperative Smoking and Alcohol Cessation Intervention on Health-related Quality of Life in Patients Undergoing Radical Cystectomy: A Randomised Controlled Trial.
    Eur Urol Focus. 2025;11:940-950.
    PubMed         Abstract available


    Eur Urol Oncol

  39. LEUNG DK, Wong CH, Ko IC, Siu BW, et al
    Global Trends in the Incidence, Mortality, and Risk-attributable Deaths for Prostate, Bladder, and Kidney Cancers: A Systematic Analysis from the Global Burden of Disease Study 2021.
    Eur Urol Oncol. 2025;8:1533-1543.
    PubMed         Abstract available


    Eur Urol Open Sci

  40. LIU K, Liu AQ, Zhao H, Wong CH, et al
    Impact of H1 Antihistamines on Bacillus Calmette-Guerin-treated Non-muscle-invasive Bladder Cancer.
    Eur Urol Open Sci. 2025;83:23-29.
    PubMed         Abstract available


    Expert Rev Mol Diagn

  41. TOMASSEN YL, Gibb EA, Lotan Y, de Jong JJ, et al
    Unlocking the potential of long non-coding RNAs in bladder cancer.
    Expert Rev Mol Diagn. 2025 Dec 13:1-4. doi: 10.1080/14737159.2025.2603407.
    PubMed         Abstract available


    FEBS Open Bio

  42. LEYPOLD S, Riese J, Seillier L, Kuhnel M, et al
    Tumor-stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer.
    FEBS Open Bio. 2025 Dec 12. doi: 10.1002/2211-5463.70179.
    PubMed         Abstract available


    Fr J Urol

  43. MOLLOT-GRANGER S, Chabrot P, Xardel V, Charbonnel C, et al
    Interim analysis of the IRMAA study: concordance between MRI and histopathological analysis of bladder cancer.
    Fr J Urol. 2025 Dec 10:103065. doi: 10.1016/j.fjurol.2025.103065.
    PubMed         Abstract available

  44. CHAPUIS M, Wandoren W, Haudebert C, Richard C, et al
    Ureteroenteric repair for strictures after radical cystectomy and urinary diversion: Comparison of the open and robotic approaches.
    Fr J Urol. 2025;35.
    PubMed         Abstract available

  45. CHABENES M, Fiard G, Blanc N, Delay M, et al
    Functional and urodynamics outcomes after robot-assisted cystoprostatectomy with intracorporeal neobladder: Impact of the learning curve.
    Fr J Urol. 2025;35:102997.
    PubMed         Abstract available


    Front Genet

  46. GUO X, Li G
    SHMT2 modulates the transcriptome and metabolism profiles to promote the tumor phenotypes of bladder cancer HT-1376 cells.
    Front Genet. 2025;16:1694089.
    PubMed         Abstract available


    Front Immunol

  47. POLAK L, Hojeij R, Cesson V, Haefliger JA, et al
    Characterization of Ty21a immunostimulatory effects in the mouse bladder.
    Front Immunol. 2025;16:1629462.
    PubMed         Abstract available

  48. LANGFELDER P, Lin ET, Tsai YT, Cha TL, et al
    Gene signature for response prediction to immunotherapy and prognostic markers in metastatic urothelial carcinoma.
    Front Immunol. 2025;16:1607222.
    PubMed         Abstract available

  49. DONG X, Fu X, Zhang H, Ma Y, et al
    Durable complete response to PD-1 inhibitor in vesical calculus-associated squamous cell carcinoma: a case report.
    Front Immunol. 2025;16:1688443.
    PubMed         Abstract available


    Front Oncol

  50. RUOJING W, Yuan S, Feiya S, Lijuan Y, et al
    Deep learning-based survival analysis of bladder cancer patients in the Putuo District, Shanghai, China.
    Front Oncol. 2025;15:1619309.
    PubMed         Abstract available

  51. HU X, Xie T, Xiao X, Mei Y, et al
    LncRNA ELDR promotes bladder cancer malignant progression by regulating the miR-1343-3p/TRIM44 axis.
    Front Oncol. 2025;15:1685792.
    PubMed         Abstract available


    Healthcare (Basel)

  52. HOU Y, Zhang Q, Ma B
    Kidney, Prostate, and Bladder Cancer Burden Attributable to Tobacco Smoke Exposure in BRICS Countries from 1990 to 2021: A Systematic Analysis Based on the Global Burden of Disease Study.
    Healthcare (Basel). 2025;13:3082.
    PubMed         Abstract available


    Histopathology

  53. LOPEZ-BELTRAN A, Blanca A, Downes MR, Cimadamore A, et al
    Molecular pathology of bladder cancer.
    Histopathology. 2026;88:65-85.
    PubMed         Abstract available

  54. DOWNES MR, van der Kwast TH, Lopez-Beltran A, Cheng L, et al
    Grading of bladder cancer: updates, controversies and practical solutions.
    Histopathology. 2026;88:86-107.
    PubMed         Abstract available

  55. WOJCIK EM
    The Paris system for reporting urinary cytology: what worked and what still needs to be improved.
    Histopathology. 2026;88:131-136.
    PubMed         Abstract available

  56. AKBULUT D, Al-Ahmadie H
    Neuroendocrine tumours of the urinary bladder: recent advances.
    Histopathology. 2026;88:108-121.
    PubMed         Abstract available


    Indian J Pathol Microbiol

  57. VENKATAKRISHNAN S, Jinkala SR, Sreerag KS, Kayal S, et al
    Basal subtype of invasive urothelial carcinoma of the bladder has aggressive behavior and poor prognosis: An immunohistochemistry-based study.
    Indian J Pathol Microbiol. 2025;68:736-743.
    PubMed         Abstract available


    Int J Mol Sci

  58. BRAUN JP, Palattao KAD Jr, Torbenson E, Hsia B, et al
    Genomic Characteristics of Bladder Cancer: An AACR Project GENIE Study.
    Int J Mol Sci. 2025;26:11653.
    PubMed         Abstract available


    Int J Nanomedicine

  59. CHEN Y, Zheng B, Liu Z, Wang H, et al
    Dual-Spherical Multifunctional Nanomotors for Intravesical Bladder Cancer Therapy.
    Int J Nanomedicine. 2025;20:14613-14628.
    PubMed         Abstract available


    Int J Surg

  60. YU N, Li J, Cao D, Chen X, et al
    CT-based radiomics signature of visceral adipose tissue for prediction of early recurrence in patients with NMIBC: a multicentre cohort study.
    Int J Surg. 2025;111:9457-9470.
    PubMed         Abstract available


    Int J Urol

  61. MIYAKE M, Nishimura N, Taoka R, Miki J, et al
    Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette-Guerin (BCG) Therapy in BCG-Naive or -Unresponsive Non-Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025 Dec 12. doi: 10.1111/iju.70314.
    PubMed         Abstract available

  62. SHIOZAKI M, Minagawa T, Yokoyama H, Hirotsu Y, et al
    Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Nonmuscular-Invasive Urothelial Bladder Cancer.
    Int J Urol. 2025 Dec 9. doi: 10.1111/iju.70293.
    PubMed         Abstract available

  63. HORI T, Nohara T, Kawahara T, Nakagawa R, et al
    Association Between Preoperative 5-Aminolevulinic Acid Administration Timing and Perioperative Hypotension.
    Int J Urol. 2025;32:1827-1833.
    PubMed         Abstract available

  64. NOMURA N, Sekino Y, Hayashi T, Kobayashi G, et al
    TUBB3 Is Associated With a Poor Prognosis and Basal Subtypes in Upper and Lower Tract Urothelial Carcinoma.
    Int J Urol. 2025;32:1893-1901.
    PubMed         Abstract available

  65. KOBATAKE K, Goto K, Hatayama T, Naito M, et al
    Efficacy of Open-Ended Urinary Catheters in Preventing Catheter-Related Bladder Discomfort: A Randomized Controlled Trial.
    Int J Urol. 2025;32:1819-1826.
    PubMed         Abstract available


    Int Urol Nephrol

  66. ZHANG W, Wei Q, Han X, Zheng X, et al
    Global, regional, and national burdens of bladder cancer in individuals aged 60 years and older from 1990 to 2021: a cross-sectional study.
    Int Urol Nephrol. 2025 Dec 9. doi: 10.1007/s11255-025-04941.
    PubMed         Abstract available

  67. SONG Z, Wang Y, Yu C, Sha K, et al
    ZSTK474 suppresses bladder cancer cell migration and invasion via PI3K/Akt/Girdin pathway: an in vitro study.
    Int Urol Nephrol. 2025 Dec 5. doi: 10.1007/s11255-025-04940.
    PubMed         Abstract available


    J Cachexia Sarcopenia Muscle

  68. ENGELMANN SU, Kasparbauer F, Pickl C, Del Giudice F, et al
    Interplay of IL-6, GDF-15 and Sarcopenia in Patients With Bladder Cancer Undergoing Radical Cystectomy and Its Implications on Survival.
    J Cachexia Sarcopenia Muscle. 2025;16:e70146.
    PubMed         Abstract available


    J Ethnopharmacol

  69. LIU YX, Song YS, Liu CK, Liu J, et al
    Paris polyphylla Smith var. yunnanensis-derived saponins potentiate the antitumor activity of GPX4 inhibitors.
    J Ethnopharmacol. 2026;357:120890.
    PubMed         Abstract available


    J Exp Clin Cancer Res

  70. PANNHAUSEN J, Chughtai AA, Yuce CL, Melzer MK, et al
    Targeting ATR offers multifaceted treatment strategies involving RAD51-mediated compensatory DNA repair in bladder cancer.
    J Exp Clin Cancer Res. 2025 Dec 12. doi: 10.1186/s13046-025-03603.
    PubMed        


    J Natl Cancer Inst

  71. LIU B, Floud S, Yang L, Yang TO, et al
    Prospective associations of diabetes with 15 cancers in 2.2 million UK and Chinese adults.
    J Natl Cancer Inst. 2025;117:2477-2487.
    PubMed         Abstract available


    J Transl Med

  72. TANAKA S, Wilkens LR, Marchand LL, Yang G, et al
    Developing a prediction model in a large case-control study for the early detection of bladder cancer.
    J Transl Med. 2025 Dec 5. doi: 10.1186/s12967-025-07511.
    PubMed        


    J Urol

  73. CHANG SS, Chamie K, Kramolowsky E, Gonzalgo ML, et al
    Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder
    J Urol. 2026;215:44-56.
    PubMed         Abstract available


    JAMA Ophthalmol

  74. PAN WW, Waters I, Yousif J, Reichert ZR, et al
    Acute and Substantial Vision Loss After Pembrolizumab Immunotherapy for Bladder Cancer.
    JAMA Ophthalmol. 2025 Dec 11. doi: 10.1001/jamaophthalmol.2025.5068.
    PubMed        


    JCO Oncol Pract

  75. ABIDOYE O, Jain P, Singh P
    Lines of Therapy for Locally Advanced/Metastatic Urothelial Carcinoma: The New Paradigm.
    JCO Oncol Pract. 2025;21:1765-1773.
    PubMed         Abstract available


    Medicine (Baltimore)

  76. BAI J, Wang L
    Blood urea nitrogen and bladder cancer: A Mendelian randomization study.
    Medicine (Baltimore). 2025;104:e46046.
    PubMed         Abstract available

  77. CHAI J, Feng R, Wang A, Zhang T, et al
    Ectopic adrenal tissue around the prostate: A rare case.
    Medicine (Baltimore). 2025;104:e46287.
    PubMed         Abstract available


    Mol Oncol

  78. SCHLOSSER RM, Krumbach F, Corrales E, Andrieux G, et al
    Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal-like and malignant urothelial cells.
    Mol Oncol. 2025;19:3784-3805.
    PubMed         Abstract available


    Molecules

  79. SILVA A, Felix AM, Goncalves CS, Longatto-Filho A, et al
    Functional and Mechanistic Insights of 3-Hydroxybutyrate (3-OBA) in Bladder Cancer.
    Molecules. 2025;30:4624.
    PubMed         Abstract available


    NPJ Digit Med

  80. LIU J, Sun S, Guo Y, Gu Z, et al
    Integrative molecular-radiopathomic characterization of AIRE-driven immune subtypes in bladder cancer.
    NPJ Digit Med. 2025 Dec 14. doi: 10.1038/s41746-025-02091.
    PubMed         Abstract available


    Oncoimmunology

  81. RUIZ-LORENTE I, Gimeno L, Lopez-Abad A, Cubillana PL, et al
    HLA class-I genotyping to personalize Bacille Calmette-Guerin immunotherapy in bladder cancer.
    Oncoimmunology. 2025;14:2598920.
    PubMed         Abstract available


    Oncol Rev

  82. SINGH V, Singh MK, Kumar A, Shrivastava A, et al
    DNA methylation as prognostic factors in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Oncol Rev. 2025;19:1679974.
    PubMed         Abstract available


    Oncologist

  83. SUN M, Ju M, Zhang H, Huang N, et al
    Clinical characteristics of the ALK fusion-positive bladder PMP and efficacy of lorlatinib: a two-case report and literature review.
    Oncologist. 2025;30:oyaf389.
    PubMed         Abstract available


    Phys Med

  84. SAPIGNOLI S, Bettinelli A, Caricato P, Amico AG, et al
    Bladder surface-based analysis proves the advantages of online adaptive radiotherapy over plan of the day.
    Phys Med. 2025;140:105677.
    PubMed         Abstract available


    Planta Med

  85. YANG CW, Chen CY, Yen CH, Shu CW, et al
    Threo-2,3-bis-(4-hydroxy-3-methoxyphenyl)-3-methoxypropanol (THMP) Inhibits Bladder Cancer Cell Proliferation via Oxidative Stress-dependent Apoptosis and DNA Damage.
    Planta Med. 2025 Dec 8. doi: 10.1055/a-2752-9897.
    PubMed         Abstract available


    PLoS One

  86. VUORISTO L, Poyhonen A, Vuorlaakso SM, Kotsar A, et al
    Hyperglycemia and bladder cancer prognosis in a Finnish population-based cohort.
    PLoS One. 2025;20:e0338215.
    PubMed         Abstract available

  87. FREY LJ, Banasiewicz KE, Ruckes C, Wagner I, et al
    Complications and oncologic outcome in bladder cancer patients receiving radical cystectomy after intravesical instillation treatment.
    PLoS One. 2025;20:e0337644.
    PubMed         Abstract available


    Radiother Oncol

  88. SARGOS P, Pignot G, Bellera C, Pommier P, et al
    Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART/GETUG-AFU30).
    Radiother Oncol. 2025;214:111326.
    PubMed         Abstract available


    Res Rep Urol

  89. LU LL, Chen HZ, Chen JG
    Impact of Age, TNM Stage, and Hospitalization on Bladder Cancer Survival: Evidence from a Hospital-Based Cohort in Eastern China.
    Res Rep Urol. 2025;17:481-493.
    PubMed         Abstract available


    Res Vet Sci

  90. HOGGARD NK, Elshafae SM, Daniels NA, Young JA, et al
    Comparative histologic survey and transcriptomic investigation into canine prostate carcinoma.
    Res Vet Sci. 2026;198:105981.
    PubMed         Abstract available


    Sci Rep

  91. ZHANG W, Deng LL, Xia YY, Wei MY, et al
    Multi-omics profiling identifies ESM1 as a key mediator of immunoevasion through the SPP1 pathway in bladder cancer.
    Sci Rep. 2025;15:43439.
    PubMed         Abstract available

  92. MAO Q, Liu H, Liu S, Wang W, et al
    Uncovering the prognostic implications and immunological roles of transmembrane protein 208 in bladder cancer by multi omics analysis and experimental verification.
    Sci Rep. 2025;15:43503.
    PubMed         Abstract available


    Semin Nucl Med

  93. SAFARIAN A, Muin D, Unterrainer L, Hormann A, et al
    The role of non-FDG agents in PET imaging of bladder cancer.
    Semin Nucl Med. 2025 Dec 8:S0001-2998(25)00165.
    PubMed         Abstract available


    Theranostics

  94. XU Y, Du Q, Zhao Z, Fu S, et al
    Targeted Accumulation of Reactive Acrolein via Nanoparticle-embedded Reverse Temperature Hydrogel for Bladder Cancer Treatment.
    Theranostics. 2026;16:1528-1544.
    PubMed         Abstract available


    Transl Androl Urol

  95. ABOU CHAKRA M, Duquesne I, Mima M, Moussa M, et al
    Global insights into the management of BCG-unresponsive non-muscle invasive bladder cancer: a narrative review of provider surveys.
    Transl Androl Urol. 2025;14:3782-3793.
    PubMed         Abstract available

  96. HAN K, Wei C, Li Y, Luo Y, et al
    Integration of genetic, proteomic, and transcriptomic data identifies therapeutic targets and prognostic biomarkers in bladder cancer.
    Transl Androl Urol. 2025;14:3472-3492.
    PubMed         Abstract available


    Transl Oncol

  97. SHI Y, Sun J, Yu K, Lu D, et al
    piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1 mRNA destabilization.
    Transl Oncol. 2025;63:102626.
    PubMed         Abstract available


    Urol Oncol

  98. MYERS AA, Duan Z, Igel DA, Steinmetz AR, et al
    Disparities and temporal trends in referral for bladder cancer diagnosis: A worsening epidemic.
    Urol Oncol. 2025 Dec 10:S1078-1439(25)00477.
    PubMed         Abstract available

  99. GOKHALE P, Akosah A, Villa Zapata L
    Immune-related adverse events associated with immune checkpoint inhibitor therapy in bladder cancer patients: A systematic review and meta-analysis.
    Urol Oncol. 2025 Dec 10:S1078-1439(25)00470.
    PubMed         Abstract available

  100. CHANG JC, Perez-Londono A, Kaul S, Almohtasib J, et al
    Dynamic prognostication of non-muscle invasive bladder cancer using conditional recurrence- and progression-free survival: A SEER-Medicare analysis.
    Urol Oncol. 2025 Dec 9:S1078-1439(25)00452-1. doi: 10.1016/j.urolonc.2025.
    PubMed         Abstract available

  101. KAYAR K, Kayar R, Sonmez D, Hakan MT, et al
    Evaluation of kynurenine and tryptophan metabolism in bladder cancer: Diagnostic and prognostic implications of IDO1 polymorphism.
    Urol Oncol. 2025 Dec 8:S1078-1439(25)00475-2. doi: 10.1016/j.urolonc.2025.
    PubMed         Abstract available

  102. SAVAGE SJ, Ercole CE, Hemstreet G, Leone A, et al
    Diagnostic performance of Cxbladder Triage Plus for the identification and stratification of patients at risk for urothelial carcinoma: The multicenter, prospective, observational DRIVE study.
    Urol Oncol. 2026;44:65.
    PubMed         Abstract available

  103. ZENG J, Tachibana I, Sadowski J, Yeap Y, et al
    Comparison of 4 local anesthetic techniques for open radical cystectomy: A prospective, randomized controlled trial.
    Urol Oncol. 2026;44:64.
    PubMed         Abstract available

  104. ARTILES MEDINA A, Minguez Ojeda C, Subiela JD, Lopez Curtis D, et al
    A systematic review and meta-analysis evaluating the incidence, microbiological profile and risk factors associated with urinary tract infection after radical cystectomy.
    Urol Oncol. 2025 Oct 28:S1078-1439(25)00399.
    PubMed         Abstract available

  105. JINDAL T, Jiang CY, Alhalabi O, Davidsohn M, et al
    Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.
    Urol Oncol. 2026;44:65.
    PubMed         Abstract available

  106. KEARNEY M, Macmillan T, Poritz J, Schreiber-Gosche S, et al
    Measuring what matters to patients: Systematic literature review of patient-reported outcomes assessment and reporting in locally advanced or metastatic urothelial cancer real-world and clinical studies.
    Urol Oncol. 2026;44:63.
    PubMed         Abstract available

  107. LAMA DJ, Jaime-Casas S, Imam A, Okunowo O, et al
    Renal ultrasound as a surveillance method for ureteroenteric anastomotic stricture following radical cystectomy and urinary diversion.
    Urol Oncol. 2026;44:64.
    PubMed         Abstract available


    Urology

  108. CHOI IW, Ebert KM, Li Q, Finup JL, et al
    A Rare Case of Ewing Sarcoma Presenting in the Adult Bladder-Treatments and Need for More Discussion.
    Urology. 2025;206:90-93.
    PubMed         Abstract available


    Value Health

  109. CAO X, Brouwer E, Chen Y, Ramsey S, et al
    Influence of initial imaging modality on peri-diagnostic outcomes among pancreatic, liver, ovarian, and bladder cancers without routine screening programs: A SEER-Medicare Study.
    Value Health. 2025 Dec 6:S1098-3015(25)06149-2. doi: 10.1016/j.jval.2025.
    PubMed         Abstract available


    Vet Immunol Immunopathol

  110. YOKOTA S, Fujii W, Motegi T, Komori M, et al
    Sorafenib inhibits myeloid-derived suppressor cell infiltration in canine transitional cell carcinoma.
    Vet Immunol Immunopathol. 2025;290:111019.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.